{"url_path":"/sec/cldx/8-k/2026-06-26/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/744218/0001104659-26-078023-index.html","accession_number":"0001104659-26-078023","cik":"0000744218","ticker":"CLDX","issuer_name":"Celldex Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/744218/0001104659-26-078023-index.html","primary_entity_key":"0000744218","primary_entity_name":"Celldex Therapeutics, Inc."},"word_count":149,"has_tables":true,"body_markdown":"**Item 5.02. Departure of Directors or Certain Officers; Election\nof Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn June 25, 2026, at the 2026 Annual Meeting\nof Stockholders (the “Annual Meeting”) of Celldex Therapeutics, Inc. (the “Company”), the Company’s\nstockholders approved an amendment (the “Plan Amendment”) to the Company’s 2021 Omnibus Equity Incentive Plan (the “2021\nPlan”) (i) increasing the number of shares available for issuance under the 2021 Plan by 3,400,000 shares and (ii) clarifying\nthe tax withholding provisions applicable to awards under the 2021 Plan. The Plan Amendment became effective following its approval by\nthe Company’s stockholders.\n\n \n\nThe foregoing description of the Plan Amendment\ndoes not purport to be complete and is qualified in its entirety by reference to the full text of the Plan Amendment, which is filed as\nExhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein."}